Evidence map›Paper›PMID 32859385›Full record

ArticleAtherosclerosis2020

Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.

Loukianos S Rallidis, Evangelos N Liberopoulos, Charalambos Vlachopoulos, Ioannis Skoumas, Genovefa Kolovou, Georgia Anastasiou, Ioanna Dima, Dimitrios Tousoulis, Efstathios Iliodromitis

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Atherosclerosis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Loukianos S Rallidis2nd Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece. Electronic address: lrallidis@gmail.com.
Evangelos N LiberopoulosDepartment of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Charalambos Vlachopoulos1st Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
Ioannis Skoumas1st Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
Genovefa KolovouCardiometabolic Center, Lipoprotein Apheresis and Lipid Disorders Clinic, Metropolitan Hospital, Athens, Greece.
Georgia AnastasiouDepartment of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Ioanna Dima1st Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
Dimitrios Tousoulis1st Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
Efstathios Iliodromitis2nd Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anticholesteremic AgentsCardiovascular DiseasesDyslipidemiasHyperlipoproteinemia Type IICholesterol, LDLHumansProprotein Convertase 9Risk FactorsAnticholesteremic AgentsCholesterol, LDLPCSK9 protein, humanProprotein Convertase 9Familial hypercholesterolaemiaLDL-Cholesterol targetLipid-lowering therapyPCSK9 inhibitorsVery-high risk

Identifiers

PMID32859385

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.